Literature DB >> 24767858

Combination of hepatocellular markers is useful for prognostication in gastric hepatoid adenocarcinoma.

Mikako Osada1, Shinichi Aishima1, Minako Hirahashi1, Nobuyoshi Takizawa1, Shunsuke Takahashi1, Kazuhiko Nakamura2, Masao Tanaka3, Yoshihiko Maehara4, Ryoichi Takayanagi2, Yoshinao Oda5.   

Abstract

Hepatoid or α-fetoprotein (AFP)-producing adenocarcinomas of stomach growing in a solid pattern are highly aggressive tumors. It is difficult to detect hepatoid differentiation solely based on findings from hematoxylin and eosin stainings, especially in small biopsy specimens. Gastric adenocarcinomas with hepatoid differentiation should be distinguished from solid-type gastric adenocarcinoma because of their different biological behavior. We immunohistochemically analyzed hepatocellular markers (AFP, glypican 3, and Hepatocyte paraffin 1 [HepPar-1]) and possible markers of gastric hepatoid adenocarcinoma (Sal-like protein 4 [SALL4] and palate, lung, and nasal epithelium carcinoma-associated protein [PLUNC]) to detect hepatoid differentiation in 45 gastric hepatoid adenocarcinomas and 47 nonhepatoid solid-type poorly differentiated adenocarcinomas. There were a higher incidence of vascular invasion (P = .0055) and distant metastasis (P = .0458) in hepatoid adenocarcinoma than in nonhepatoid adenocarcinoma. AFP, SALL4, HepPar-1, and glypican 3 were significantly higher in hepatoid adenocarcinoma than in nonhepatoid adenocarcinoma. All 5 markers were positive in both the hepatoid/solid and the tubular component. In hepatoid adenocarcinoma, the frequency of distant metastasis was significantly higher in SALL4-negative cases than in SALL4-positive cases (P = .0381). HepPar-1 was associated with liver metastasis (P = .0452). PLUNC was correlated with lymph node metastasis (P = .0375). There was a significant difference in the survival rate between HepPar-1-positive and HepPar-1-negative groups (P = .0437). The coexpression of PLUNC and SALL4 and the other coexpression of HepPar-1 and PLUNC were associated with poorer prognosis (P = .0181 and P = .0443, respectively). AFP, SALL4, HepPar-1, and glypican 3 are useful for the detection of hepatoid differentiation. A combination of PLUNC, HepPar-1, and SALL4 could be a reliable prognostic indicator in hepatoid adenocarcinoma of the stomach.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HepPar-1; Hepatoid adenocarcinoma; PLUNC; SALL4; Solid

Mesh:

Substances:

Year:  2014        PMID: 24767858     DOI: 10.1016/j.humpath.2014.02.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

Review 1.  [Gastric tumors and tumor precursors].

Authors:  C Röcken
Journal:  Pathologe       Date:  2017-03       Impact factor: 1.011

2.  Clinicopathological Characteristics and Prognosis of Hepatoid Adenocarcinoma of the Stomach: Evaluation of a Pooled Case Series.

Authors:  Xiang-Yu Zeng; Yu-Ping Yin; Hua Xiao; Peng Zhang; Jun He; Wei-Zhen Liu; Jin-Bo Gao; Xiao-Ming Shuai; Guo-Bin Wang; Xiu-Li Wu; Kai-Xiong Tao
Journal:  Curr Med Sci       Date:  2018-12-07

Review 3.  SALL4, the missing link between stem cells, development and cancer.

Authors:  Hiro Tatetsu; Nikki R Kong; Gao Chong; Giovanni Amabile; Daniel G Tenen; Li Chai
Journal:  Gene       Date:  2016-02-16       Impact factor: 3.688

4.  [Hepatocellular carcinomas and their mimics].

Authors:  H-P Fischer; D Goltz
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

Review 5.  Functional and clinical significance of SALL4 in breast cancer.

Authors:  Ebubekir Dirican; Mustafa Akkiprik
Journal:  Tumour Biol       Date:  2016-07-21

6.  Hepatoid adenocarcinoma of the stomach is a special and easily misdiagnosed or missed diagnosed subtype of gastric cancer with poor prognosis but curative for patients of pN0/1: the experience of a single center.

Authors:  Yibin Xie; Zhonghai Zhao; Peng Li; Yang Wang; Chunguang Guo; Xiaoliang Wang; Wei Tang; Qian Liu; Ning Lu; Liyan Xue; Dongbing Zhao
Journal:  Int J Clin Exp Med       Date:  2015-05-15

7.  SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma.

Authors:  Gang Deng; Lei Zhu; Feizhou Huang; Wanpin Nie; Wei Huang; Hongbo Xu; Shaopeng Zheng; Zhongjie Yi; Tao Wan
Journal:  Oncotarget       Date:  2015-09-29

Review 8.  PRISMA-Compliant Article: Clinical Characteristics and Factors Influencing Prognosis of Patients With Hepatoid Adenocarcinoma of the Stomach in China.

Authors:  Bao-Ge Qu; Wei-Min Bi; Bao-Teng Qu; Tao Qu; Xing-Hai Han; Hui Wang; Yuan-Xun Liu; Yi-Guo Jia
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 9.  Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis.

Authors:  Lorenzo Nicolè; Tiziana Sanavia; Nicola Veronese; Rocco Cappellesso; Claudio Luchini; Paolo Dabrilli; Ambrogio Fassina
Journal:  Oncotarget       Date:  2017-04-04

10.  Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: a meta‑analysis of individual studies.

Authors:  Ji Cheng; Jinbo Gao; Xiaoming Shuai; Kaixiong Tao
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.